McKesson Corporation vs Sunrun Inc — how do they compare? McKesson Corporation trades at $936.87 (market cap $108.46B), while Sunrun Inc trades at $7.55 (market cap $1.83B). The key difference: McKesson Corporation is far larger — about 59.3× Sunrun Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Sunrun Inc for 16 Days on average.
| MCK | RUN | |
|---|---|---|
Market Cap | $108.46B | $1.83B |
Volume | 712,607 | 8,672,852 |
Sector | Health | Energy |
52-Week High | $995.69 | $21.41 |
52-Week Low | $725.17 | $7.59 |
Typical Hold Time | 74 Days | 16 Days |
Enterprise Value | $115.00B | $16.35B |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Sunrun (RUN) trades at $7.58, down 0.39% on the day, reflecting a bearish technical trend. The stock shows attractive valuation ratios with a P/E of 5.16 and P/S of 0.59, while recent quarterly earnings have consistently beaten expectations. However, cash flow from operations remains negative, and the company faces headwinds from high borrowing costs impacting the solar sector. Positive developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing.
The outlook is mixed: strong analyst support with a $16.33 price target suggests significant upside, but operational cash burn and sector volatility pose risks. Investors should weigh low valuations against execution challenges and macroeconomic pressures affecting solar financing.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →